volitinib

Small moleculeexperimental

Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. It has been given conditional approval for these indication in China. — Wikipedia

Clinical trial activity

15 trials · 17 clinical orgs · 0 marketing orgs

Phase 1
9
Phase 2
8
Phase 3
1
Phase 4
0

Earliest trial started Feb 1, 2012 (NCT01773018)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2017

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1h-pyrazol-4-yl)-1h-(1,2,3)triazolo(4,5-b)pyrazine
  • azd6094
  • azd6094
  • azd6094
  • azd-6094
  • azd-6094
  • hmpl-504
  • hmpl-504
  • hmpl-504
  • savolitinib
  • savolitinib
  • savolitinib
  • savolitinib
  • volitinib
  • volitinib
  • volitinib
  • volitinib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03091192Phase 3May 17, 2017AstraZeneca, Harvard University, Hutchison MediPharma
NCT02447380Phase 2Mar 1, 2017Sungkyunkwan University
NCT02630420Phase 1Jan 1, 2017Yale University
NCT02897479Phase 2Oct 1, 2016Hutchison MediPharma, Jiao Tong University
NCT02819596Phase 1/Phase 2 (Phase 2)May 1, 2016AstraZeneca, University of London
NCT02761057Phase 2Apr 5, 2016National Cancer Institute (NCI), Southwest Oncology Group
NCT02449551Phase 2Feb 10, 2016Sungkyunkwan University
NCT02447406Phase 1/Phase 2 (Phase 2)Apr 30, 2015Sungkyunkwan University
NCT02374645Phase 1Apr 1, 2015AstraZeneca, Hutchison MediPharma, Shantou University
NCT02252913Phase 1Sep 1, 2014AstraZeneca, Fudan University, Hutchison MediPharma
NCT02143466Phase 1Aug 5, 2014AstraZeneca
NCT02127710Phase 2Apr 1, 2014AstraZeneca, SCRI Development Innovations
NCT02017236Phase 1Nov 1, 2013Hutchison MediPharma, Shanghai Xuhui District Central Hospital
NCT01985555Phase 1May 1, 2013Hutchison MediPharma
NCT01773018Phase 1Feb 1, 2012Hutchison MediPharma, Monash University, University of Melbourne, University of Washington, University of Western Australia
Showing 15 of 15 trials
Page 1 / 1

Organizations

Research & Development (17)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Hutchison MediPharmaFor profit7632012
AstraZenecaFor profit6332014
Sungkyunkwan UniversityAcademic/Hospital3312015
Fudan UniversityAcademic/Hospital1012014
Harvard UniversityAcademic/Hospital1012017
Jiao Tong UniversityAcademic/Hospital1012016
Monash UniversityAcademic/Hospital1012012
National Cancer Institute (NCI)Government1112016
SCRI Development InnovationsFor profit1012014
Shanghai Xuhui District Central HospitalAcademic/Hospital1012013
Shantou UniversityAcademic/Hospital1012015
Southwest Oncology GroupAcademic/Hospital1012016
University of LondonAcademic/Hospital1112016
University of MelbourneAcademic/Hospital1012012
University of WashingtonAcademic/Hospital1012012
University of Western AustraliaAcademic/Hospital1012012
Yale UniversityAcademic/Hospital1112017
17 organizations
Page 1 / 1